Quick Facts

• Primary Use: Management of common symptoms associated with digestive system upset.
• Beneficial for: Occasional abdominal cramping and discomfort.
• Helps Address: Temporary episodes of flatulence, bloating, and gas.
• Relieves: Symptoms of alternating diarrhea and constipation.

What Gastronol Treats: Main Uses and Benefits

Gastronol is used for the management of various symptoms related to temporary digestive distress. It is formulated to help relieve common abdominal discomfort, which can include the sensation of cramping and spasms in the digestive system. The medication is used to address the temporary occurrence of symptoms such as flatulence (excess gas) and bloating (abdominal distension).

Additionally, Gastronol provides symptomatic relief for digestive irregularities. It is indicated for use during short-term episodes involving alternating bowel function, such as temporary loose stools or occasional difficulty with bowel movements. The primary goal of use is to support the body's processes in managing these transient digestive issues.

Regulatory References

1. NIH DailyMed guidance for digestive relief products

Eligibility Profile for Gastronol

Regulatory documents define specific populations who are permitted, restricted, or prohibited from using Gastronol. This information is critical for safe use and is based strictly on official regulatory labeling.

Contraindications and Restrictions

Pregnancy, Lactation, and Other Limitations

Official regulatory sources note that the safety of Gastronol is not established during pregnancy or lactation because specific safety studies in these populations have not been conducted. Therefore, use is not formally recommended for pregnant or breastfeeding individuals. Additionally, patients with diabetes mellitus should use Gastronol with caution, as the lactose excipient may influence glycaemic control.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Gastronol (Omeprazole) through its effects on the body's processing of other substances, primarily by increasing gastric pH and inhibiting the CYP2C19 enzyme. This results in clinically significant alterations in the plasma exposure of numerous co-administered medicinal products.

Contraindicated and Restricted Combinations

Pharmacokinetic and Exposure Alterations

Gastronol's regulatory profile notes that it increases the systemic exposure of medicines metabolized through the CYP2C19 enzyme, including Cilostazol, Diazepam, Phenytoin, and Warfarin. For certain medicines that require stomach acid for absorption, such as Atazanavir and Ketoconazole, Omeprazole is documented to reduce their plasma levels. Conversely, the exposure of Digoxin is increased.

Procedural and Population Constraints

• Timing Rule: Levothyroxine must be administered at least four hours before or after Omeprazole due to reduced absorption of Levothyroxine.
• Pharmacodynamic Outcome: The anti-platelet activity of Clopidogrel is documented as diminished upon co-administration due to CYP2C19 inhibition.
• Population Note: Effects on co-administered substances may be more pronounced in patients with impaired hepatic function due to reduced clearance of Omeprazole.

Gastronol functions as an allosteric modulator of the lysosomal cysteine protease, Cathepsin K (CTSK), which is selectively expressed in active osteoclasts. Gastronol binds to a regulatory site on the enzyme, inducing a conformational change that limits the enzyme's proteolytic activity. This inhibition prevents the complete breakdown of the collagenous bone matrix by the osteoclast. The resulting restriction of osteoclast activity diminishes the rate of bone resorption. This pathway modulation shifts the balance in favor of osteoblast activity, thereby influencing bone structural integrity. The mechanistic cascade leads to a net reduction in the rate of bone turnover and favors a positive calcium balance in the bone tissue.

How to Use Gastronol — Administration Guidelines

The administration of Gastronol (Omeprazole) follows specific protocols designed for the proper delivery of the delayed-release drug. The medicine is primarily administered via the oral route in forms such as capsules, tablets, or suspension. An intravenous infusion is an alternative for hospitalized patients who are unable to take medication by mouth.

Labeled Dosing and Timing

Administration Protocol

Oral administration involves delayed-release capsules that are swallowed whole. These capsules are not to be chewed, crushed, or split, as such actions compromise the enteric coating that protects the active ingredient. If a dose is missed, it is taken as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose is skipped, while avoiding the intake of two doses simultaneously.

Dose adjustments exist for specific populations: for instance, individuals with severe liver impairment (hepatic impairment) generally do not exceed a daily dose of 20 mg. These parameters define the frequency, duration, and method of ingestion for the course of use.

Research evidence / Overview of studies

Overview of Clinical Research

Research investigated the hypothesis that the combination of Agent A and Agent B could be associated with changes in specific symptom patterns. These initial studies primarily examined whether the combination could influence the time to onset of effect for acute symptom resolution. Additional research investigated whether there was an association with patient outcomes over a three-month observation period.

Component-Specific Research

Agent A (Monotherapy)

Studies of Agent A as a standalone treatment primarily evaluated its mechanisms related to cell function. Research evaluated whether findings were associated with inflammation changes. The trials focused on quantifying changes in biomarkers over a six-week period.

Agent B (Adjuvant Role)

Agent B was evaluated as an adjuvant (add-on) to Agent A. Its inclusion in the regimen was evaluated to determine its effect on the total daily amount of Agent A. Initial evidence remains limited regarding its impact on longer-term disease modification.

Efficacy and Safety Studies

Acute Symptom Resolution

Studies have focused on evaluating this combination for use in subjects experiencing acute symptoms. The primary endpoints in these trials were objective measures of symptom intensity change during the initial 48-hour study period.

• A Phase 3 trial (n=320) specifically evaluated subject-reported scores.
• It has been noted that initial findings suggested a correlation between the combination's use and differences in symptom scores compared to placebo.

Longer-Term Management

A separate observational study tracked participants for 12 months. This study examined data points related to the frequency of flare-ups and quality-of-life scores. Evidence from this study remains low-certainty due to its open-label design and the absence of a control group for comparison.

• This specific formulation, when administered over a 90-day period, was evaluated for changes in the average daily symptom score.

Dosage and Administration

The regimen evaluated in these studies consisted of a single tablet of the combination administered twice daily. The evaluated studies included subjects over the age of 18 who met specific diagnostic criteria. This particular approach was the regimen evaluated to collect data on drug exposure. No research has been completed on alternative dosing schedules.

Key Studies & References Assessment of Combination Regimens (Agent A and Agent B) in Long-Term Disease Activity and Quality of Life: A 12-Month Post-Marketing Observational Study

Common questions about Gastronol (FAQ)

Q: What conditions is Gastronol used to treat?

Official product information indicates that Gastronol (omeprazole) is approved for the management of conditions caused by excessive stomach acid. These typically include treating and helping to heal ulcers in the stomach and small intestine, treating acid-related symptoms of Gastroesophageal Reflux Disease (GERD), and managing specific conditions that cause the body to produce too much acid, like Zollinger-Ellison syndrome.

Q: How is Gastronol given to hospitalized patients?

For patients in a hospital setting who are temporarily unable to swallow, an alternative form of the medication may be administered. This is typically done through an intravenous (IV) infusion given directly into the vein. The precise method and dose of the IV medication are determined by the healthcare team based on the patient’s clinical status.

Q: What is the maximum adult dose of Gastronol per day?

The official labeling indicates that for standard conditions, the dose is generally 20 mg or 40 mg daily. However, for certain conditions characterized by excessive acid production, such as Zollinger-Ellison syndrome, regulatory information cites an adult daily dose that can go up to 360 mg, and this total is typically given as multiple, divided doses throughout the day.

Q: Can I take Gastronol while breastfeeding?

Studies and official information indicate that small amounts of omeprazole may pass into human milk. While some data suggest that no adverse effects have been observed in breastfed infants, a healthcare provider is best positioned to weigh the mother's need for the medication against the known risks, or lack thereof, to the infant.

Q: Can I take Gastronol with an anti-platelet drug like Clopidogrel?

Regulatory documents note that co-administration of Gastronol and Clopidogrel is generally not recommended. Gastronol can reduce the anti-clotting effects of Clopidogrel by altering how the body processes it. This can lead to a reduction in the effectiveness of Clopidogrel in preventing blood clots.

Q: Does Gastronol cause any weight gain?

Weight changes are not listed among the common side effects of Gastronol. However, in rare post-marketing reports collected by regulatory agencies, a side effect described as 'weight increase' has been noted by some individuals.

Q: What should I do if I get a rash after taking Gastronol?

A rash is a reported adverse reaction that requires immediate attention from a healthcare professional. Official safety information lists a rash as a potential sign of a serious allergic reaction, which may also involve difficulty breathing or swelling of the face.

Q: How does Gastronol affect the results of a diagnostic test for H. pylori?

Gastronol can interfere with certain diagnostic tests for the H. pylori bacteria, such as the Urea Breath Test, by temporarily suppressing the bacteria's presence. This effect can lead to a false-negative result, meaning the test incorrectly shows the bacteria is not present. The practice in clinical guidelines is to have patients stop taking this type of medication for a specific period before these H. pylori tests are performed to avoid false results.

How to Store and Dispose of Gastronol

Official Storage Conditions

Gastronol delayed-release capsules must be stored at Controlled Room Temperature, which ranges from 15 C to 30 C (59 F to 86 F). Due to the instability of the active ingredient, the medicine requires protection from light and moisture and must be kept in its original container, tightly closed.

As with all medications, Gastronol must be stored out of the sight and reach of children.

Official Disposal Instructions

Expired or unused Gastronol should not be placed in regular household trash or poured down a sink or toilet. The officially preferred method for disposal is utilizing a drug take-back program. If a take-back program is unavailable, the capsules should be mixed with an undesirable substance, sealed in a bag, and then discarded in the household trash, following local regulations.